Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
MNT.TO 0.69COPX 1.55U.U.TO 0.27SII.TO 5.37IPCO.TO -0.2DC.A.TO 0.3NESN-SIX 0MCK 27.62
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.44
+0.47 (1.66%)
as of Aug 25, 2026, 6:15:49 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
TOP PICK

Pfizer Inc(PFE)

Sep 07, 2005
His model price is $37.65, an 46% differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.51

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 31, 2005
Very cheap on the numbers, but they have a patent issue on their largest drug, Lippitor. If they lost Lippitor, you would be looking at a stock below $20 overnight. There's a lot of risk in the name.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$25.48

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2005
Have recently added this to his fund. Good free cash flow, strong balance sheet. There is some risk right now with their Lipitor drug. A group in India is making a generic version.
Photo of Peter HofstraPeter Hofstra
Owned
Unlock Rating
$25.36

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Aug 12, 2005
Have done a lot of restructuring. Will cut their costs which will help. Part of the problem in the pharmaceutical industry has been the poor leadership in the FDA. A cheap stock and you're getting paid a 3.5% yield. Trades at a very low multiple.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.16

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 09, 2005
It's in a big trading range of $25/29. Don't let it go below the low of $24. Hopefully it will break up through the trend line. You should be in this for at least 2 years.
Photo of Bill CarriganBill CarriganUnlock Rating
$26.70

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 04, 2005
Has a model price of $38.43.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.60

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 20, 2005
They beat the numbers today. Numbers are pretty low. They are taking costs out. The problems with these stocks, which are all innovation dependent, is essentially depletion through generics.
Photo of Danny TomkaDanny Tomka
No
Unlock Rating
$27.06

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 19, 2005
Prefers the US health care stocks as they are much larger and much more seasoned. The big pharma has been a very difficult area. This one has been under a bit of a cloud, but it's cheap on an earnings basis.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$27.38

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 13, 2005
Growth rate went from 30% three years ago to almost low single digits or flat. Not performing well. The group is in the early stages of a turn around, but would be more inclined to buy the company that has flourished through this period. Would prefer Abbott Labs (ABT-N).
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$27.23

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 06, 2005
The whole area has been beaten up and is very interesting. The big pharmas have a big challenge as the pipelines are a little bit bare. Would rather own companies that are suppliers to the pharmas, such as IMS Health (RX-N). (He doesn't follow big caps.)
Photo of Phil TallerPhil Taller
No
Unlock Rating
$26.77

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 02, 2005
RE:Call options Jan/07. Not particularily expensive as it has not been a volatile stock. Not a bad way to play the stock if you are bullish on the company. The company has a very good dividend, so call option are less than the put options quite often. (His play on this is through the Vipers (VHT-A).)
Photo of Richard CroftRichard Croft
No
Unlock Rating
$27.50

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 25, 2005
Got in on the Celebrex recall. This company has developed some fantastic drugs. Pharmaceutical stocks in the US have been absolutely decimated. Dirt cheap. 3.5% didvidend yield while you wait for a recovery. Generates a ton of free cash flow. Merck & Company (MRK-N) are in the same way.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
Owned
Unlock Rating
$27.03

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 11, 2005
This company, along with the other drug stocks, has had a very big problem. Fell below its 200 day moving average. There is no base.
Photo of Ron MeiselsRon Meisels
No
Unlock Rating
$26.46

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 28, 2005
(A Top Pick Jan24/05. Up 8%.) Still likes.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.23

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Mar 21, 2005
Pharmaceuticals have pretty good cash flows, but their stocks are going nowhere. Cheap on a relative basis to where they've been. Have one big overhang as a group, i.e., there are a lot of patent expiries that are going to happen in 2006. May not be a bad time to start picking them up.
Photo of Martin Hubbes, CFAMartin Hubbes, CFA
Owned
Unlock Rating
$25.71

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 661 to 675 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

IESC -10.86$313.26
NTR.TO -2.19$100.68
TFPM 0$
OGC.TO 0.08$43.3
SLB -0.545$53.455

Today's Top Picks

MNT.TO 0.69$69.95
COPX 1.55$96.08
U.U.TO 0.27$20.69
SII.TO 5.37$192.56
IPCO.TO -0.2$35.02

Popular Articles

Latest Sell Signals

RKLB -1.06$67.22
INTC 0.41$87.67
MSFT 3.81$491.12
WSP.TO -2.98$189.3
CLS.TO 14.99$422.35

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like